- Home
- / Aquestive Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Aquestive Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$5.7
2024-10-29
Market Capitalization
$515.4 M
2024-10-29
Revenue
$44.5 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 50.8M | 47.7M | 50.6M | 57.6M | 44.5M |
| Cost of goods sold | 15.0M | 19.4M | 20.8M | 17.9M | 18.6M |
| Gross profit | 35.8M | 28.3M | 29.8M | 39.7M | 26.0M |
| Gross profit margin, % | 70.5% | 59.3% | 58.8% | 69.0% | 58.3% |
| General and administrative expense | 53.5M | 52.9M | 31.8M | 50.2M | 79.8M |
| Operating expense total | 70.5M | 70.4M | 44.9M | 70.5M | 97.0M |
| EBIT | (34.7M) | (42.1M) | (15.1M) | (30.8M) | (71.1M) |
| EBIT margin, % | -68.2% | -88.2% | -29.9% | -53.5% | -159.5% |
| Interest expense | 10.0M | 6.6M | 6.3M | 7.1M | |
| Pre tax profit | (70.5M) | (54.4M) | (7.6M) | (44.2M) | (83.8M) |
| Income tax expense | 245.0K | (14.0K) | |||
| Net Income | (70.5M) | (54.4M) | (7.9M) | (44.1M) | (83.8M) |
| EPS | (1.8) | (1.1) | (0.5) | (0.8) |